Lisata Therapeutics patent granted for certepetide method of use
Lisata Therapeutics said the USPTO granted a new method of use patent for certepetide for pancreatic cancer and other solid tumors.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Lisata wins patent for certepetide cancer use
Lisata Therapeutics said the USPTO granted a new method-of-use patent for certepetide in pancreatic cancer and other solid tumors. The patent is slated to expire in May 2041, with the company citing added market exclusivity into November 2043.
Lisata Therapeutics patent granted for certepetide method of use
Lisata Therapeutics (LSTA) said it received a new method of use patent granted for certepetide covering treatment of pancreatic cancer and other solid tumors.